Lower all-cause death, fewer HF events with empagliflozin in acute HF | Latest news for Doctors, Nurses and Pharmacists | Pharmacy

Lower all-cause death, fewer HF events with empagliflozin in acute HF | Latest news for Doctors, Nurses and Pharmacists | Pharmacy

Lower all-cause death, fewer HF events with empagliflozin in acute HF Patients hospitalized with acute heart failure (HF) have a reduced risk of subsequent HF events or all-cause mortality if treated with once-daily empagliflozin while in hospital, according to results of the EMPULSE trial presented at HFSA 2022. Participants were 530 adults hospitalized with acute HF (de novo or decompensated chronic HF) regardless of ejection fraction (EF) or diabetes status. To be included, patients needed to have systolic blood pressure …